A COMPARISON OF THE IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST, TOTAL COLONOSCOPY AND FLEXIBLE SIGMOIDOSCOPY FOR DETECTION OF ADVANCED NEOPLASIA

This is an automatically generated default intro template – please do not edit.

	Read full article
Article Title:	A COMPARISON OF THE IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST, TOTAL COLONOSCOPY AND FLEXIBLE SIGMOIDOSCOPY FOR DETECTION OF ADVANCED NEOPLASIA
Authors:	Iovănescu Dana1, Carmen Neamtu1*, Miuţescu Eftimie1, Miutescu Bogdan Petru1, Burlea Amelia, Ciprian Duta3, Bogdan Totolici1
Affiliation:	1„Vasile Goldiş” Western University of Arad – Faculty of Medicine, Pharmacy and Dental Medicine, Arad, Romania 2Department of Pathology, County Hospital Arad, Romania 3„ Victor Babes” University of Medicine and Pharmacy Timisoara, Second Surgical Clinic, Timisoara, Romania
Abstract:	Colorectal cancer is a major health issue in the European Union but the disease is particularly suitable for screening. Screening for colorectal cancer using fecal occult blood testing, flexible sigmoidoscopy, or colonoscopy is recommended. The aim of this study was to compare the effectiveness of colonoscopy, flexible sigmoidoscopy and fecal immunochemical tests in detecting advanced neoplasic lesions. A number of 45 patients, 21 males and 24 females, were investigated using colonoscopy, flexible sigmoidoscopy and fecal immunochemical tests. Colonoscopy found 9 patients with advanced neoplasia: 6 with cancer and 3 with advanced adenomas. Fecal immunochemical test were positive in 4 cases of advanced neoplasia and flexible sigmoidoscopy revealed 3 cases. Colonoscopy is the mainstay in colorectal cancer screening but fecal immunochemical tests and flexible sigmoidoscopy can also play a role, because compared with no screening, any of the common screening strategies will reduce mortality.
Keywords:	screening, colorectal carcinoma, advanced neoplasia, adenoma, colonoscopy, sigmoidoscopy, fecal immunochemical tests
References:	Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 Kinzler KW, Vogelstein B. Colorectal tumors. In: Vogelstein B, Kinzler KW, eds. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill, 2002:583-612. Markowitz SD, Bertagnolli MM Molecular Origins of Cancer Molecular Basis of Colorectal Cancer N Engl J Med 2009;361:2449-60 Bresalier RS, Colorectal Cancer in Sleisenger and Fordtran’s Gastrointestinal and Liver Disease Pathophysiology/Diagnosis/Management Ninth Edition 2010 Elsevier p 2191-2238 Feldman M, Friedman LS, Brandt LJ, MD Quirke P, Risio M, Lambert R, von Karsa L, Vieth M. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition–Quality assurance in pathology in colorectal cancer screening and diagnosis. Endoscopy, 2012; 44(3):SE 4-16, 105-114, 116-130. U.S. Preventive Services Task Force Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2008;149:627-637. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-Effectiveness Analyses of Colorectal Cancer Screening: A Systematic Review for the US Preventive Services Task Force. Ann Intern Med, 2002; 137:96-104. Popescu A, Sporea I: Screeningul cancerului de colon între ideal şi posibilităţi. Editura Mirton, Timişoara, 2009; 9-20, 45-103 Miutescu B, Sporea I, Popescu A, Bota S, Iovănescu D, Burlea A, Mos L, Miutescu E . Results of faecal immunochemical test forcolorectal cancers creening, in average risk population, in a cohort of 1389 subjects, Clujul Medical 2013 Vol. 86 – no. 2 Miutescu B, Sporea I, Popescu A, Bota S, Iovănescu D, Miutescu E . Adherence to a colorectal cancer screening using the faecal immunochemical test Studia Universitatis “Vasile Goldiş”, Seria Ştiinţele Vieţii Vol. 23, issue 2, 2013, pp. 111-114
*Correspondence:	Carmen Neamtu Str. Gradinarilor Nr.43 Arad, Romania Mobile: 0723225793 Mail: carmen.neamtu@gmail.com